Exparel Approved for Post-Surgery Pain

Provides relief up to 72 hours

MONDAY, Oct. 31 (HealthDay News) -- Exparel (bupivacaine liposome injectable suspension) has been approved by the U.S. Food and Drug Administration to treat post-surgical pain, maker Pacira Pharmaceuticals said Monday.

The product combines the long-acting anesthetic bupivacaine with Pacira's DepoFoam delivery technology. A single dose can provide relief for up to 72 hours and reduce the need for opioid painkillers, the drug maker said in a news release.

Exparel was evaluated in 21 clinical studies, including more than 1,300 participants. The most common side effects reported included nausea, constipation, and vomiting, Pacira said.

The company is based in Parsippany, N.J.

More information

To learn more about pain, visit Medline Plus.

Copyright © 2011 HealthDay. All rights reserved.

Powered by

jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles Recommended Nursing Articles

Abdominal Pain: An Approach to a Challenging Diagnosis
AACN Advanced Critical Care, July/September 2014
Free access will expire on October 13, 2014.


HIPAA Compliance Practice Tips
Professional Case Management, July/August 2014
Free access will expire on September 29, 2014.


Follow the leader: How does “followership” influence nurse burnout?
Nursing Management, August 2014
Free access will expire on September 29, 2014.


More Recommended Articles

Subscribe to Recommended Articles

Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events